ZOMETA® Effectively Inhibits Bone Destruction in ZOMETA® Lung Cancer Patient Case Study
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

Anthony P.
  • Aged 64 years
  • Retired auto mechanic
  • Quit smoking 10 years ago
Page  1 2 3

ZOMETA® effectively inhibits the vicious cycle of bone destruction in patients like Anthony when given 4 mg every 3 to 4 weeks10

  • Bone resorption marker decreases rapidly following administration of ZOMETA on day 111
  • The effect of ZOMETA on bone resorption marker lessens after 3 to 4 weeks11


Change from baseline in bone resorption marker*
(after single 4-mg dose of ZOMETA; N=12)11
*Urinary N-telopeptide/creatinine ratio was chosen as the surrogate marker.


Only dosing every 3 to 4 weeks has been proven effective in reducing
or delaying SREs2,12-14




Page  1 2 3